Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Expands By 55.9%

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a large growth in short interest in July. As of July 31st, there was short interest totaling 45,910 shares, a growth of 55.9% from the July 15th total of 29,440 shares. Based on an average daily trading volume, of 25,260 shares, the short-interest ratio is presently 1.8 days. Currently, 0.1% of the company’s stock are sold short.

Barinthus Biotherapeutics Trading Up 0.4%

NASDAQ:BRNS opened at $0.59 on Tuesday. Barinthus Biotherapeutics has a twelve month low of $0.51 and a twelve month high of $1.83. The company has a market cap of $24.24 million, a PE ratio of -0.58 and a beta of -0.39. The company’s 50 day moving average is $0.63 and its two-hundred day moving average is $0.64.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Several hedge funds have recently made changes to their positions in the company. Rangeley Capital LLC lifted its position in Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after acquiring an additional 75,024 shares during the period. Renaissance Technologies LLC grew its stake in Barinthus Biotherapeutics by 115.8% during the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after purchasing an additional 76,800 shares during the last quarter. Finally, Baird Financial Group Inc. increased its holdings in shares of Barinthus Biotherapeutics by 108.2% in the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after purchasing an additional 100,000 shares during the period. 25.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.